These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 18375889)

  • 1. Optimal schedule of paclitaxel: weekly is better.
    Gonzalez-Angulo AM; Hortobagyi GN
    J Clin Oncol; 2008 Apr; 26(10):1585-7. PubMed ID: 18375889
    [No Abstract]   [Full Text] [Related]  

  • 2. Paclitaxel prodrugs: toward smarter delivery of anticancer agents.
    Skwarczynski M; Hayashi Y; Kiso Y
    J Med Chem; 2006 Dec; 49(25):7253-69. PubMed ID: 17149855
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer.
    Ramalingam S; Perry MC; La Rocca RV; Rinaldi D; Gable PS; Tester WJ; Belani CP
    Cancer; 2008 Aug; 113(3):542-6. PubMed ID: 18512224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrent chemoradiotherapy with weekly paclitaxel in malignant cerebral glioma treatment.
    Montemor JP; Peria FM; Monti CR; Petrilli LS; Colli BO; Carlotti Júnior CG
    Onkologie; 2008 Sep; 31(8-9):435-9. PubMed ID: 18787350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer.
    Braly P; Nicodemus CF; Chu C; Collins Y; Edwards R; Gordon A; McGuire W; Schoonmaker C; Whiteside T; Smith LM; Method M
    J Immunother; 2009 Jan; 32(1):54-65. PubMed ID: 19307994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies.
    Fracasso PM; Picus J; Wildi JD; Goodner SA; Creekmore AN; Gao F; Govindan R; Ellis MJ; Tan BR; Linette GP; Fu CJ; Pentikis HS; Zumbrun SC; Egorin MJ; Bellet RE
    Cancer Chemother Pharmacol; 2009 Feb; 63(3):451-8. PubMed ID: 18414864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies.
    Mita M; Mita A; Sarantopoulos J; Takimoto CH; Rowinsky EK; Romero O; Angiuli P; Allievi C; Eisenfeld A; Verschraegen CF
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):287-95. PubMed ID: 19034451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintenance therapy for ovarian cancer: of Helsinki and Hippocrates.
    McGuire WP
    J Clin Oncol; 2009 Oct; 27(28):4633-4. PubMed ID: 19704055
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful treatment with three-weekly paclitaxel of an anthracycline-refractory classical Kaposi's sarcoma.
    Silvestris N; Galetta D; Colucci G
    Anticancer Res; 2009 Feb; 29(2):675-6. PubMed ID: 19331220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical investigation of weekly Carboplatin and Paclitaxel with concurrent radiation therapy for locally advanced non-small cell lung cancer].
    Mito A; Yamasaki M; Matsuura K; Kajihara T; Nitta T; Awaya H; Arita K; Kashiwado K; Ohashi N
    Gan To Kagaku Ryoho; 2009 Oct; 36(10):1653-6. PubMed ID: 19838022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
    Mehta RS; Schubbert T
    J Natl Cancer Inst; 2008 May; 100(9):680; author reply 680-1. PubMed ID: 18445822
    [No Abstract]   [Full Text] [Related]  

  • 12. Albumin-bound paclitaxel: new drug. Breast cancer metastases: no progress.
    Prescrire Int; 2009 Feb; 18(99):8-9. PubMed ID: 19382399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
    Ozols RF
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent chemoradiotherapy for malignant glioma: dead end or highway?
    Mirimanoff RO
    Onkologie; 2008 Sep; 31(8-9):430-1. PubMed ID: 18787348
    [No Abstract]   [Full Text] [Related]  

  • 15. Protein nanoparticles as drug carriers in clinical medicine.
    Hawkins MJ; Soon-Shiong P; Desai N
    Adv Drug Deliv Rev; 2008 May; 60(8):876-85. PubMed ID: 18423779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A retrospective analysis of adverse events based on a dose and a schedule in patients who underwent paclitaxel- containing chemotherapy].
    Yoshimura T; Hirade K; Iihara H; Ishihara M; Komori Y; Okayasu S; Matsuura K; Yasuda T; Itoh Y
    Gan To Kagaku Ryoho; 2008 Oct; 35(10):1721-6. PubMed ID: 18931576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of weekly paclitaxel for advanced or metastatic breast cancer in Japan.
    Horiguchi J; Rai Y; Tamura K; Taki T; Hisamatsu K; Ito Y; Seriu T; Tajima T
    Anticancer Res; 2009 Feb; 29(2):625-30. PubMed ID: 19331212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility of endoscopic ultrasound-guided OncoGel (ReGel/paclitaxel) injection into the pancreas in pigs.
    Linghu E; Matthes K; Mino-Kenudson M; Brugge WR
    Endoscopy; 2005 Nov; 37(11):1140-2. PubMed ID: 16281147
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase II trials in journal of clinical oncology.
    Cannistra SA
    J Clin Oncol; 2009 Jul; 27(19):3073-6. PubMed ID: 19451415
    [No Abstract]   [Full Text] [Related]  

  • 20. [Comparison of the pharmacokinetics and safety of a paclitaxel injection NK and Taxol injection in breast cancer patients].
    Sagara Y; Rai Y; Sagara Y; Matsuyama Y; Baba S; Tamada S; Sagara Y; Ando M
    Gan To Kagaku Ryoho; 2009 Feb; 36(2):247-50. PubMed ID: 19223739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.